1


Board -2023 -Mtg -04-Doc 00a


Gavi Alliance Board Meeting
6-7 December 2023
Kempinski Hotel, Accra, Ghana
Wednes day 6 December : 08. 00-18. 30 (Board meeting Day One)
T hur sday 7 December : 08.00 -17 .00 (Board meeting Day Two)
Quorum: 14

Document List

No. Document
00a Document list
00b Agenda
01a Declarations of interest
01b Minutes from 26-27 June 2023
01c Minutes from 11 September 2023
01d No Objection Consent Decisions
01e Consent Agenda
01f Workplan
02 Country Presentation – Ghana – No paper
0 3 CEO’s Report – To follow
04 Strategy, Programmes and Partnerships: Progress, Risks and Challenges
0 5 Country Programmes Delivery Presentation – No paper
06 Committee Chair and IFFIm Board reports – To follow
0 7 Financial Update, including forecast
08 Update from Ethics, Risk and Compliance Office
0 9 Road to Replenishment – To follow
10a Gavi’s Role in Pandemic Prevention, Preparedness and Response: Pandemic
Prevention, Preparedness and Response Approach
10b Gavi’s role in Pandemic
Prevention, Preparedness and Response: African
Vaccine Manufacturing Accelerator (AVMA)
11 Vaccine Investment Strategy 2024: Proposed Shortlist
1 2 COVAX Update

Board -202 3-Mtg -04-Doc 00b 1

Gavi Alliance Board Meeting
6-7 December 2023
Kempinski Hotel, Accra, Ghana

Sunday 3, Monday 4 and Tuesday 5 December: Pre -Board meetings &
Field Visits
Tuesday 5 December: 09.00 -17.00 Board Retreat
Wednesday 6 December : 08. 00 -18. 30 Board M eeting Day One
Thursday 7 December : 0 8.00 -17.00 Board M eeting Day Two

Quorum: 14



A genda - REVISED














Next Board Meeting : 17-18 April 2024 (Board Retreat)
26 -27 June 2024
4-5 December 2024
---
Brenda Killen , Director, Governance and Secretary to the Board, +41 22 909 6680, bkillen@gavi.org
Joanne Goetz , Head, Governance, +41 22 909 6544, jgoetz@gavi.org
Please note that the Board meeting will be recorded. This recording will be used as an aid to minute the
meeting. A transcription of the full proceedings will not normally be made. Should a transcription be made it
will be used only as an aid to minute the meeting.

1

Board -2023 -Mtg -04-Doc 01a

Gavi Alliance Board Meeting
6-7 December 2023
Kempinski Hotel, Accra, Ghana
Quorum: 14
Declarations of Interest
Declarations
Section 5.5 of the Conflicts of Interest Policy for Governance Bodies states “Members involved
in decision- making processes on behalf of Gavi must take appropriate action to ensure
disclosure of Interests and Conflicts of Interest, and take the necessary action in respect
thereof.”

Section 6.2 of the Conflicts of Interest Policy for Governance Bodies further states, “The duty
to disclose [in 6.1 above] is a continuing obligation. This means that Members are obliged to
disclose any Interests and/or Conflict of Interest, whenever the Member comes to know the
relevant matter.”

The following declarations were made by members of the Board on their most recent annual
statements .

Board members:
Member
Organisational Interests Financial/Personal/Advisor Int/
Others













José Manuel Barroso,
Chair
























None












Hult – EF (Education First) (Visiting
Professor and Chair of Advisory
Council) ; Goldman Sachs (Chair of
International Advisors from 1 April
2023) ; Princeton University Princeton
School of Public Policy, LISD (Member
of the Advisory Council from 01 April
2023) ; CAPRI, Center for Asia Pacific
Resilience and Innovation (Member of
the International Advisory Council from
1 April 2023); Catholic University of
Portugal (Visiting Professor at the
Institute of Political Studies and Director
of the Centre for European Studies) ;
The EUROPEAUM (Board Member) ;
WPL Women Political Leaders
(Advisory Board Member) ; Jean Monnet
Foundation for Europe (Honorary
Committee Member); European Centre
for Culture, (Honorary Co-P resident);
Portuguese Diaspora Council
(Chairman of the General Assembly
and Chairman of the EurAfrican
Forum); Bilderberg Meetings (Steering
Committee Member); Concordia
(Member of the Leadership Council) ;

Board -202 3-Mtg -02 1
Minutes

Gavi Alliance Board Meeting
26 -27 June 2023
Global Health Campus, Geneva, Switzerland

1. Chair’s report

1.1 Noting that the meeting had been duly convened and finding a quorum of
members present, the meeting commenced at 14 .05 Geneva time on
26 June 202 3. Prof Jos é Manuel Barroso, Board Chair, chaired the meeting.

1.2 The Chair welcomed new Board members and Alternate members attending
for the first time, namely: Eduardo Retes of Honduras , Greg Widmyer of the Bill
& Melinda Gates Foundation and Me llissa Hisko of Canada .

1.3 The Chair welcomed a number of high -level observers from Brazil, Saudi
Arabia , South Africa and Spain . He also welcomed Kenneth Lay, International
Finance Facility for Immunisation (IFFIm ) Board Chair , and other directors of
the IFFIm Board , as well as representatives from Nestor Advisors , the external
firm which is undertaking the ongoing Board and Board Committee evaluation.

1.4 He provided a brief summary on a number of preparatory meetings that took
place on the eve of the Board meeting , including the meeting of the
Implementing Country Caucus and the All Chairs Group (ACG) .

1.5 The Chair highlighted the Gavi Mid -Term Review (MTR) event that had taken
place on 13 -15 June 2023 in Madrid at the invitation of the Government of
Spain , whom he thanked for their commitment to global health. He underlined
the importance of the MTR in reviewing the progress of Gavi ’s objectives and
commended the Alliance for reaching the milestone of 1 billion children
vaccinated since Gavi’s inception in 2000.

1.6 The Chair noted that during the closed session earlier that day he had informed
the Board of a critical development related to the CEO position. Dr Muhamm ad
Pate , who was expected to assume his role as the new Gavi CEO on
3 August 2023 had informed Prof Barroso on the eve of the Board meeting that
he will not be able to join Gavi as he has accepted a request to return and
contribute to his home country , Nigeria . The Chair explained that in view of this
the Board had agreed to appoint the Chief Operating Officer (COO) David
Marlow, as interim CEO (and therefore a non -voting Board member) until a new
CEO has been recruited . He noted that the Board had also received an update
from Mr Marlow on the Operational Excellence initiative during the closed
session .

1.7 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack).

Board -202 3-Mtg -03 1
Minute s
Gavi Alliance Board Meeting
11 September 2023
Virtual

1. Chair’s report

1.1 Noting that the meeting had been duly convened and finding a quorum of
members present, the meeting commenced at 14 .01 Geneva time on
11 September 2 02 3. Prof José Manuel Barroso, Board Chair, chaired the
meeting .

1.2 The Chair welcomed Sai Prasad as a new Board Member . He noted that
Alexandra Rudolph -Seeman was exceptionally attending this closed session as
an observer for Germany, the anchor donor for their donor constituency cluster.

1.3 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack).

1.4 The Chair informed Board Members of his intention to extend the deadline for
expressions of interest in the position of Board Vice Chair to
29 September 2023, noting that the process had been launched during a period
when many may ha ve been on leave and may not have been able to give the
process due consideration.

1.5 He also updated the Board on a recent trip he had made to China for Gavi
during which he had had a number of impor tant high -level meetings at which
he had been able to highlight Gavi’s role as a key partner for China. He noted
the support received in preparing for this visit from Gavi Board Member, Yibing
Wu.

--- ---

2. Update on CEO Search Process

2.1 The Chair introduced this item recalling that the Board, in June 2023 had agreed
to re -start the ongoing CEO search and recruitment process and confirmed
member ship of the CEO Search Committee.

2. 2 He noted that, as requested by the Governance Committee, Gavi’s Chief
People and Experience Officer, Laura McKeaveney, led the task of identifying
a search firm, negotiating the contract, and ensuring the chosen firm meet s the
highest industry standards in this recruitment and that she will continue to be
available as needed by the Committee and the Board going forward.

2.3 The Chair then reported that the Search Committee had met three times during
July and August 2023 and referred to the email that he had sent to the Board

1


Board -2023 -Mtg -04 -Doc 01d

Report to the Board
6-7 December 2023

Subject No -Objection Consent Decisions
Agenda item 01 d
Category For Information


Since the June 2023 B oard meeting, three decisions have been circulated
electronically for approval by no -objection consent in line with Section 11 of the Board
and Board Committee Operating Procedures.
1) On 20 July 2023 , Board Members were invited to consider approv al of the
appointment of a Programme and Policy Committee Member .

No objections were received prior to the end of 2 August 2023 and the following
decision was therefore entered into the record:

In accordance with Section 11.3 of the Board and Board Committee Operating
Procedures, on a no -objection basis, the Gavi Alliance Board:

Appointed P. Ashok Babu (Committee Delegate) to the Programme and Policy
Committee, effective immediately and until 31 December 2023
2) On 20 September 2023 , Board Members were invited to consider approv al of the
appointment of Alternate Board Members and Programme and Policy
Committee Members .

No objections were received prior to the end of 2 October 2023 and the following
decision was therefore entered into the record:

In accordance with Section 11.3 of the Board and Board Committee Operating
Procedures, on a no -objection basis, the Gavi Alliance Board:

a) Appointed Soleh Ayubi as Alternate Board Member to Sai Prasad
re presenting the vaccine industry developing countries in the seat which is
currently vacant, effective 1 October 2023 and until 30 September 2025

b) Appointed Karin Berlin as Alternate Board Member to John -Arne Røttingen
representing Sweden on the donor constituency cluster anchored by Norway in
the seat which is currently vacant, effective immediately and until 30 June 2024

c) Appointed the following to the Programme and Policy Committee effective
immediately:
• Hannah Haaij (Committee Delegate) until 31 December 2023

1


Board -2023 -Mtg -04-Doc 01e

Report to the Board
6-7 December 2023

Subject Consent Agen da – as at 5 December 2023
Agenda item 01 e
Category For Decision

Section A : Introduction
Nine recommendations are being presented to the Board under the Consent Agenda
for consideration. Detailed information on the items can be found in the relevant
Committee papers in a dedicated folder on BoardEffect at:
https://gavi.boardeffect.co.uk/workrooms/6459/resources/245825
Section B : Actions Requested of the Board
The Gavi Alliance Board is requested to consider the following recommendations from
the Gavi Alliance Governance Committee and the Gavi Alliance Programme and
Policy Committee .
Decision One – Board Vice Chair Nomination
The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board
that it:
Appoint Omar Abdi as Vice Chair of the Board with individual signatory authority,
effective 1 January 2024 and until 31 December 2025.
Decision Two – Board and Committee Appointments
The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board
that it:
a) Appoint the following Board Members:

• Jérémie Forrat -Jaime as Board Member representing France on the donor
constituency anchored by Germany in the seat currently held by Gabriella
Fésüs of the European Commission , effective 1 January 2024 and until
31 December 2024 .
• Karin Berlin as Board Member representing Sweden on the donor
constituency anchored by Norway in the seat currently held by John Arne
Røttingen of Norway , effective 1 January 2024 and until
31 December 2025 .

gavi.org
FINANCIAL UPDATE, INCLUDING FINANCIAL FORECAST
BOARD MEETING
Assietou Diouf
6 -7 December 2023, Accra, Ghana
Assumptions driving financial
update
• Resources US$ +157 m
o Driven by investment income
and foreign exchange
movements
• Expenditure US$ (21) m
o Advancement of
programmatic demand
o offset by increased working
capital efficiencies
For decision : US$ 140 m
o MMCV investment proposal
(U$ 136 m)
o Post -transition support,
Timor -Leste (U$ 4 m)
Sufficient resources available
• Forecasts confirm sufficient
resources to support Board
decisions submitted
• Limited additional flexibility remains
Change drivers 6.0 COVAX Core
2
Gavi Core (2021 - 2025)
US$ 103 million remains available for future investments
June 2023
Board
Higher
programmatic
expenditure
For decision:
MMCV & post -
transition
support
Dec 2023
Board
Higher
resources

US$ 6 million
Available for future
investment
US$ 109 m
US$ 157 m
US$ (21) m
US$ (140) m
Available for future
investment
US$ 103 m
Board Meeting, 6 -7 December 2023

Click to edit Master title style
Click to edit Master subtitle style

gavi.org
D A V I D M A R L O W
CEO Board Update
B O A R D M E E T I N G
6–7 D E C E M B E R 2 0 2 3 , A C C R A , G H A N A
Contents
Board Meeting, 6 –7 December 2023
Executive summary 01
Global context & external environment 02
Gavi 5.1 delivery 03
Looking ahead; Gavi 6.0 & replenishment 04
Reflections and focus for Ghana Board meeting 05
Reaching zero -dose children ,
including with malaria vaccine,
Oti region, Ghana
Gavi/2023/Nipah Dennis
2

gavi.org
Strategy, Programmes &
Partnerships:
Progress, R isks and C hallenges
BOARD MEETING
Aurélia Nguyen
6 -7 December 2023, Accra, Ghana
Update photo
To be completed
To be completed
Balanced scorecard | Programmatic strategic goals
Beta version Q3 2023
1.Children immunised covers only routine immunisation, not campaigns 2. Disability Adjusted Life Years 3.Baseline for timely outbreak detection is average of 2018 –2020 ; 4.30% of countries, 65% in dollar value, best performance over last 5 years 6. Baseline for preventing backsliding set for 2021 as ofJuly 2022
Baseline
(2019) H1 2023
Breadth of protection 48% 56% (2022)
New vaccine introductions** n/a (2020) 7 (Sep 2023)
• HPV applications approved** n/a 2 (Sep 23)
• Malaria applications approved** n/a 16 (Sep 23)
Timely outbreak detection 25% 3 18% (2022)
Measles campaign reach 25% 70.2% (2022)
Strategic goal 1 Introduce and scale up vaccines
Baseline
(2019) 2022
DTP3 coverage 83% 81%
Geographic equity of DTP3 67% 62%
DTP dropout 6% 6%
MCV1 coverage 81% 79%
Strategic goal 2 Strengthen health systems
Baseline
(2021) H1 2023
Co -financing fulfilment 100% (2020) 30% 4
Preventing backsliding in
Gavi -transitioned countries 8 countries 6 8 countries
(2022)
Vaccine intro in transitioned &
never -eligible countries n/a (2022) 3 (Sep 2023)
Strategic goal 3 Improve sustainability
Baseline 2022
Healthy market dynamics n/a 10
Incentivise innovations n/a 9
Scale -up innovations n/a 2
Strategic goal 4 Ensure healthy markets
Gavi 5.0
mission indicators
Baseline
(2020) 2022
Unique children immunised 1 0 >133m (2021 -22)
Future deaths averted 0 >2.4m (2021 -22)
Reduction in zero -dose children 9m (2019) 10.2m
Future DALYs 2averted 0 >121m (2021 -22)
Economic benefits unlocked 0 >$35.8bn (2021 -22)
SG2
SG4
SG1
SG3
** Updated bi -annually or more (else updated annually)
On track Delays/challenges Significant delays/challenges No target / TBD
Board Meeting, 6 -7 December 2023

gavi.org
COUNTRY PROGRAMMES
DELIVERY
BOARD MEETING
Thabani Maphosa
Andrew Owain Jones
Kate O’Brien
6 -7 December 2023, Accra, Ghana
Priorities and
programme
performance
COUNTRY PROGRAMMES DELIVERY